The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia

Open Heart

Volumn 1, Issue 1, 2014, Pages

  Pears, Robert ^a   Griffin, Michael ^b   Watson, Melanie ^c   Wheeler, Rebecca ^d   Hilder, Debbie ^e   Meeson, Beverley ^d   Bacon, Sallie ^a   Byrne, Christopher D ^f  

^a HAMPSHIRE COUNTY COUNCIL   (United Kingdom)

^b Solutions for Public Health   (United Kingdom)

^c Wessex Clinical Genetics Service   (United Kingdom)

^d West Hampshire CCG   (United Kingdom)

^e Health Education Wessex   (United Kingdom)

^f University of Southampton   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; GENERIC DRUG; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DUAL CARE MODEL; ENGLAND; FAMILIAL HYPERCHOLESTEROLEMIA; GENERAL PRACTICE; GENERAL PRACTITIONER LED SERVICE; GENETIC SCREENING; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH SERVICE; HUMAN; MEDICAL SPECIALIST; PATIENT CARE; POPULATION RESEARCH; PRACTICE GUIDELINE; PREDICTION; PRIMARY MEDICAL CARE; QUANTITATIVE ANALYSIS; SPECIALIST LED SERVICE;

EID: 84984629934     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2013-000015     Document Type: Article

References (12)

1. NICE. Clinical guideline 71: identification and management of familial hypercholesterolaemia. NICE, 2008.
2. NICE. Familial hypercholesterolaemia: costing report, implementing NICE guidance. NICE, 2009.
3. Gill PJ, Harnden A, Karpe F. Easily missed? Familial hypercholesterolaemia. BMJ 2012;344:e3228.
4. Allaby M, Griffin M. Implementation of the NICE clinical guideline CG71 on familial hypercholesterolaemia: a report for the South Central Cardiovascular Network. Public Health Resources Unit, October 2009. http://heartuk.org.uk/FHToolkit/downloads/3.3/3C%20South%20Central%20Cardiac%20Network%20example.pdf Last viewed 27 Jan 2014.
5. Heart UK. Saving lives, saving families: the health, social and economic advantages of detecting and treating familial hypercholesterolaemia (FH). Heart UK, 2012.
6. Heath KE, Humphries SE, Middleton-Price H, et al. A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom. Eur J Hum Genet 2001;9:244-52.
7. Marks D, Thorogood M, Neil SM, et al. Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes. J Med Screen 2006;13:156-9.
8. London Ideas. Department of Health familial hypercholesterolaemia cascade testing audit project: recommendations to the Department of Health. London Ideas, 2007.
9. DH Cardiovascular Disease Team. Cardiovascular disease outcome strategy: improving outcomes for people with or at risk of cardiovascular disease. Department of Health, 2013.
10. NICE. QS41: quality standards for familial hypercholesterolaemia. NICE, 2013. http://publications.nice.org.uk/familial-hypercholesterolaemia-qs41 last viewed 27 Jan 2014.
11. NICE. Familial hypercholesterolaemia: costing template. NICE, 2009. http://guidance.nice.org.uk/CG71/CostingTemplate/xls/English last viewed 27 Jan 2014.
12. Shen L, Peng H, Xu D, et al. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Pharmacol Res 2013;73:27-34.